Nitric oxide inhalation - Mallinckrodt

Drug Profile

Nitric oxide inhalation - Mallinckrodt

Alternative Names: Ik 7001; IK-3001; IK-7001; INOflo; INOmax; INOmax Total Care; INOMAX® Total Care package; INOtherapy; INOVENT

Latest Information Update: 26 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Massachusetts General Hospital
  • Developer AGA Linde Healthcare; Ikaria Holdings; Mallinckrodt plc
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifungals; Antihypertensives; Antivirals; Free radicals; Macromolecular substances; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Hypoxic respiratory failure
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypoxic respiratory failure
  • Registered Pulmonary hypertension
  • Phase III Bronchopulmonary dysplasia
  • Discontinued Heart failure; Reperfusion injury

Most Recent Events

  • 23 Sep 2016 Mallinckrodt has patent protection for nitric oxide inhalation and gas delivery systems in USA
  • 23 Sep 2016 Praxair files an appeal against the Patent Trial and Appeal Board decision related to the US patent no. 8 846 112 in U.S. Court of Appeals for the Federal Circuit and Mallinckrodt also files a cross-appeal
  • 23 Sep 2016 The US Patent and Trademark Office confirms the validity of five 2031 patents protecting nitric oxide inhalation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top